Current Progresses and Trends in the Development of Progesterone Receptor Modulators.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Medicinal Chemistry

• Publication date

  2016-06-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/0929867323666160428105310PMID 27121188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent advances in structure of progestins and their binding to progesterone receptors

  2015cited by this paper
• First synthesis and characterization for the stereoisomers of Ulipristal acetate.

  2015cited by this paper
• Detection and functional portrayal of a novel class of dihydrotestosterone derived selective progesterone receptor modulators (SPRM).

  2015cited by this paper
• Development of 1,3-diphenyladamantane derivatives as nonsteroidal progesterone receptor antagonists.

  2015cited by this paper
• Is progesterone a neutral or protective factor for breast cancer?

  2014cited by this paper
• Development of p-carborane-based nonsteroidal progesterone receptor antagonists.

  2014cited by this paper
• Binge‐like ethanol consumption increases corticosterone levels and neurodegneration whereas occupancy of type II glucocorticoid receptors with mifepristone is neuroprotective

  2014cited by this paper
• Recent and current Phase II clinical trials in endometrial cancer: review of the state of art

  2014cited by this paper
• The Unique Pharmacological Characteristics of Mifepristone (RU486): From Terminating Pregnancy to Preventing Cancer Metastasis

  2014cited by this paper
• A new and efficient method for the synthesis of Ulipristal acetate.

  2014cited by this paper
• Effects of an Ethinyl Estradiol/Gestodene Transdermal Contraceptive Patch on the Endometrium: A Single-Center, Uncontrolled Study

  2014cited by this paper
• Synthesis and biological evaluation of 11' imidazolyl antiprogestins and mesoprogestins.

  2014cited by this paper
• Contraceptive use in acne.

  2014cited by this paper
• Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study.

  2014cited by this paper
• Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy

  2014cited by this paper
• A clinical trial of progesterone for severe traumatic brain injury.

  2014cited by this paper
• Design and synthesis of nonsteroidal progesterone receptor antagonists based on C,C'-diphenylcarborane scaffold as a hydrophobic pharmacophore.

  2014cited by this paper
• The "newer" progestogens and postmenopausal hormone therapy (HRT).

  2014cited by this paper
• Progesterone Reduces Cocaine Use in Postpartum Women with a Cocaine Use Disorder: A Randomized,Double-Blind Study.

  2014cited by this paper
• Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations.

  2014cited by this paper
• A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial.

  2014cited by this paper
• Synthesis and structure-activity relationship of p-carborane-based non-secosteroidal vitamin D analogs.

  2014cited by this paper
• Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors.

  2014cited by this paper
• Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition

  2014cited by this paper
• Retrospective review of norethindrone use in adolescents.

  2014cited by this paper
• Characterization, neurosteroid binding and brain distribution of human membrane progesterone receptors δ and {epsilon} (mPRδ and mPR{epsilon}) and mPRδ involvement in neurosteroid inhibition of apoptosis.

  2013cited by this paper
• A simple and convenient synthetic route to Ulipristal acetate.

  2013cited by this paper
• Protective actions of progesterone in the cardiovascular system: potential role of membrane progesterone receptors (mPRs) in mediating rapid effects.

  2013cited by this paper
• Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.

  2013cited by this paper
• Therapeutic effects of progesterone in animal models of neurological disorders.

  2013cited by this paper
• Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study.

  2013cited by this paper
• Synthesis and antiprogestational properties of novel 17-fluorinated steroids.

  2013cited by this paper
• Progesterone and neuroprotection.

  2013cited by this paper
• A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression.

  2012cited by this paper
• Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.

  2012cited by this paper
• 8-alkylthio-6-thio-substituted theophylline analogues as selective noncompetitive progesterone receptor antagonists.

  2012cited by this paper
• Progesterone and autoimmune disease.

  2012cited by this paper
• X-ray Structures of Progesterone Receptor Ligand Binding Domain in Its Agonist State Reveal Differing Mechanisms for Mixed Profiles of 11β-Substituted Steroids

  2012cited by this paper
• Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist.

  2011cited by this paper
• Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.

  2011cited by this paper
• Structural Basis for Agonism and Antagonism for a Set of Chemically Related Progesterone Receptor Modulators

  2011cited by this paper
• Discovery of a novel mechanism of steroid receptor antagonism: WAY-255348 modulates progesterone receptor cellular localization and promoter interactions.

  2011cited by this paper
• 6-arylcoumarins as novel nonsteroidal type progesterone antagonists: an example with receptor-binding-dependent fluorescence.

  2011cited by this paper
• Boron cluster-based development of potent nonsecosteroidal vitamin D receptor ligands: direct observation of hydrophobic interaction between protein surface and carborane.

  2011cited by this paper
• Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study.

  2011cited by this paper
• 1-Methyl-1H-pyrrole-2-carbonitrile containing tetrahydronaphthalene derivatives as non-steroidal progesterone receptor antagonists.

  2010cited by this paper
• Optimisation of a pyrazole series of progesterone antagonists; Part 1.

  2010cited by this paper
• A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007

  2010cited by this paper
• New-D-homoandrost-4,6-diene derivatives as potent progesterone receptor antagonist.

  2010cited by this paper
• Conservative Treatment With Medroxyprogesterone Acetate Plus Levonorgestrel Intrauterine System for Early-Stage Endometrial Cancer in Young Women: Pilot Study

  2010cited by this paper
• Aromatic beta-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists.

  2010cited by this paper
• Improving the developability profile of pyrrolidine progesterone receptor partial agonists.

  2010cited by this paper
• Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget.

  2010cited by this paper
• Met909 Plays a Key Role in the Activation of the Progesterone Receptor and Also in the High Potency of 13-Ethyl Progestins

  2009cited by this paper
• Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.

  2009cited by this paper
• 5-Aryl indanones and derivatives as non-steroidal progesterone receptor modulators.

  2009cited by this paper
• Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists.

  2009cited by this paper
• Synthesis and SAR of amino acid-derived heterocyclic progesterone receptor full and partial agonists.

  2009cited by this paper
• 2-Amino-9-aryl-3-cyano-4-methyl-7-oxo-6,7,8,9-tetrahydropyrido[2',3':4,5]thieno[2,3-b]pyridine derivatives as selective progesterone receptor agonists.

  2009cited by this paper
• Discovery and biological characterization of a novel series of androgen receptor modulators

  2008cited by this paper
• Discovery of structurally diverse nonsteroidal SPRMs based on a screening hit, 1,2-dihydro-2,2,4-trimethyl-6-phenylquinolinone.

  2008cited by this paper
• Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton.

  2008cited by this paper
• Selective progesterone receptor modulators 1: use during pregnancy

  2008cited by this paper
• SAR study of 2,3,4,14b-tetrahydro-1H-dibenzo[b,f]pyrido[1,2-d][1,4]oxazepines as progesterone receptor agonists.

  2008cited by this paper
• 11-(pyridinylphenyl)steroids--a new class of mixed-profile progesterone agonists/antagonists.

  2008cited by this paper
• Selective progesterone receptor modulators 2: use in reproductive medicine

  2008cited by this paper
• A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.

  2008cited by this paper
• Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions.

  2008cited by this paper
• Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.

  2008cited by this paper
• 7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists.

  2008cited by this paper
• Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134)

  2007cited by this paper
• (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.

  2007cited by this paper
• Development of a library of 6-arylcoumarins as candidate fluorescent sensors.

  2007cited by this paper
• The evolution of progesterone receptor ligands

  2007cited by this paper
• Array synthesis of progesterone receptor antagonists: 3-aryl-1,2-diazepines.

  2006cited by this paper
• The use of mifepristone in the treatment of neuropsychiatric disorders.

  2006cited by this paper
• Endocrinological Properties of Two Novel Nonsteroidal Progesterone Receptor Modulators, CP8816 and CP8863

  2005cited by this paper
• Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.

  2005cited by this paper
• Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications.

  2005cited by this paper
• The nuclear receptor ligand-binding domain: a family-based structure analysis.

  2005cited by this paper
• Molecular and Pharmacological Properties of a Potent and Selective Novel Nonsteroidal Progesterone Receptor Agonist Tanaproget*

  2005cited by this paper
• A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton.

  2005cited by this paper
• Potent androgen antagonists based on carborane as a hydrophobic core structure.

  2005cited by this paper
• SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists.

  2005cited by this paper
• Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists.

  2005cited by this paper
• Characterization of a new class of selective nonsteroidal progesterone receptor agonists.

  2004cited by this paper
• Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.

  2003cited by this paper
• CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton.

  2003cited by this paper
• Structure-activity relationship of nuclear receptor-ligand interactions.

  2003cited by this paper
• Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.

  2003cited by this paper
• 5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.

  2003cited by this paper
• Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines.

  2002cited by this paper
• In vitro and in vivo characterization of novel nonsteroidal progesterone receptor antagonists derived from the fungal metabolite PF1092C.

  2002cited by this paper
• New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles.

  2002cited by this paper
• 6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.

  2002cited by this paper
• Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones.

  2001cited by this paper
• Potent estrogen agonists based on carborane as a hydrophobic skeletal structure. A new medicinal application of boron clusters.

  2001cited by this paper
• Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines.

  2000cited by this paper
• Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity.

  2000cited by this paper
• Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.

  2000cited by this paper

• MiR‐423 Coding Region Genetic Polymorphism rs8067576 May Associate With the Risk of Developing Recurrent Spontaneous Abortion: A Case‐Control Study in a Chinese Han Population

  2025cites this paper
• Progesterone and prostate: a history of scientific study and the modern view of the problem

  2023cites this paper
• Functional genomic analysis of the human receptive endometrium transcriptome upon administration of mifepristone at the time of follicle rupture.

  2019cites this paper
• Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.

  2018cites this paper
• Progesterone receptor modulators for endometriosis.

  2017cites this paper